Market Overview

Benzinga's Top Initiations

Benzinga's Top Initiations

Analysts at Standpoint Research initiated coverage on Coherus Biosciences Inc (NASDAQ: CHRS) with a Speculative Buy rating. The price target for Coherus Biosciences is set to $40. Coherus Biosciences shares closed at $28.10 on Wednesday.

Latest Ratings for CHRS

Nov 2020MizuhoMaintainsBuy
Nov 2020HC Wainwright & Co.MaintainsBuy
Aug 2020Truist SecuritiesMaintainsBuy

View More Analyst Ratings for CHRS
View the Latest Analyst Ratings


Related Articles (CHRS)

View Comments and Join the Discussion!

Posted-In: Top InitiationsInitiation Analyst Ratings

Latest Ratings

TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at